| Identification | Back Directory | [Name]
Carbamic acid, N-[2-ethyl-6-[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]-8-methylimidazo[1,2-a]pyridin-3-yl]-, (3,5-dichlorophenyl)methyl ester | [CAS]
2485779-34-6 | [Synonyms]
ATX inhibitor 13
Carbamic acid, N-[2-ethyl-6-[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]-8-methylimidazo[1,2-a]pyridin-3-yl]-, (3,5-dichlorophenyl)methyl ester | [Molecular Formula]
C31H35Cl2N5O3 | [MOL File]
2485779-34-6.mol | [Molecular Weight]
596.55 |
| Hazard Information | Back Directory | [Uses]
ATX inhibitor 13 (10c) is an orally active and potent ATX inhibitor, with an IC50 of 3.4 nM. ATX inhibitor 13 inhibits proliferation and migration, and induces apoptosis and G2 phase arrest in RAW264.7 cells. ATX inhibitor 13 suppresses tumor cell colony formation[1]. | [in vivo]
ATX inhibitor 13 (compound 10c) (C57BL/6J mice, 0-1000 mg/kg, Orally, once) has an acceptable safety profile[1]. | Animal Model: | C57BL/6J mice (5 groups,4 mice per group)[1] | | Dosage: | 5000, 3200, 2500 and 1000 mg/kg | | Administration: | Orally, once | | Result: | Had an acceptable safety profile, showed no obvious safety concerns. |
| [IC 50]
ATX: 3.4 nM (IC50) | [References]
[1] Lei H, et al. Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors. Eur J Med Chem. 2022;236:114307. DOI:10.1016/j.ejmech.2022.114307 |
|
|